Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

Helen J. MacKay, Douglas A. Levine, Victoria L. Bae-Jump, Daphne W. Bell, Jessica N. McAlpine, Alessandro Santin, Gini F. Fleming, David G. Mutch, Kenneth Nephew, Nicolas Wentzensen, Paul J. Goodfellow, Oliver Dorigo, Hans W. Nijman, Russell Broaddus, Elise C. Kohn

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

Original languageEnglish (US)
Pages (from-to)84579-84594
Number of pages16
JournalOncotarget
Volume8
Issue number48
DOIs
StatePublished - 2017

Fingerprint

Endometrial Neoplasms
Clinical Trials
Genes
National Cancer Institute (U.S.)
Therapeutics
Mortality
Incidence
Pharmaceutical Preparations
Neoplasms

Keywords

  • Endometrial cancer
  • Molecular targets

ASJC Scopus subject areas

  • Oncology

Cite this

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer : NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. / MacKay, Helen J.; Levine, Douglas A.; Bae-Jump, Victoria L.; Bell, Daphne W.; McAlpine, Jessica N.; Santin, Alessandro; Fleming, Gini F.; Mutch, David G.; Nephew, Kenneth; Wentzensen, Nicolas; Goodfellow, Paul J.; Dorigo, Oliver; Nijman, Hans W.; Broaddus, Russell; Kohn, Elise C.

In: Oncotarget, Vol. 8, No. 48, 2017, p. 84579-84594.

Research output: Contribution to journalReview article

MacKay, HJ, Levine, DA, Bae-Jump, VL, Bell, DW, McAlpine, JN, Santin, A, Fleming, GF, Mutch, DG, Nephew, K, Wentzensen, N, Goodfellow, PJ, Dorigo, O, Nijman, HW, Broaddus, R & Kohn, EC 2017, 'Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials', Oncotarget, vol. 8, no. 48, pp. 84579-84594. https://doi.org/10.18632/oncotarget.19961
MacKay, Helen J. ; Levine, Douglas A. ; Bae-Jump, Victoria L. ; Bell, Daphne W. ; McAlpine, Jessica N. ; Santin, Alessandro ; Fleming, Gini F. ; Mutch, David G. ; Nephew, Kenneth ; Wentzensen, Nicolas ; Goodfellow, Paul J. ; Dorigo, Oliver ; Nijman, Hans W. ; Broaddus, Russell ; Kohn, Elise C. / Moving forward with actionable therapeutic targets and opportunities in endometrial cancer : NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. In: Oncotarget. 2017 ; Vol. 8, No. 48. pp. 84579-84594.
@article{5193e52b8df944f69e776fda47962612,
title = "Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials",
abstract = "The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.",
keywords = "Endometrial cancer, Molecular targets",
author = "MacKay, {Helen J.} and Levine, {Douglas A.} and Bae-Jump, {Victoria L.} and Bell, {Daphne W.} and McAlpine, {Jessica N.} and Alessandro Santin and Fleming, {Gini F.} and Mutch, {David G.} and Kenneth Nephew and Nicolas Wentzensen and Goodfellow, {Paul J.} and Oliver Dorigo and Nijman, {Hans W.} and Russell Broaddus and Kohn, {Elise C.}",
year = "2017",
doi = "10.18632/oncotarget.19961",
language = "English (US)",
volume = "8",
pages = "84579--84594",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "48",

}

TY - JOUR

T1 - Moving forward with actionable therapeutic targets and opportunities in endometrial cancer

T2 - NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

AU - MacKay, Helen J.

AU - Levine, Douglas A.

AU - Bae-Jump, Victoria L.

AU - Bell, Daphne W.

AU - McAlpine, Jessica N.

AU - Santin, Alessandro

AU - Fleming, Gini F.

AU - Mutch, David G.

AU - Nephew, Kenneth

AU - Wentzensen, Nicolas

AU - Goodfellow, Paul J.

AU - Dorigo, Oliver

AU - Nijman, Hans W.

AU - Broaddus, Russell

AU - Kohn, Elise C.

PY - 2017

Y1 - 2017

N2 - The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

AB - The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

KW - Endometrial cancer

KW - Molecular targets

UR - http://www.scopus.com/inward/record.url?scp=85031044089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031044089&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19961

DO - 10.18632/oncotarget.19961

M3 - Review article

AN - SCOPUS:85031044089

VL - 8

SP - 84579

EP - 84594

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 48

ER -